Abstract:Objective To analyze the value of multiple tumor-related autoantibodies in the diagnosis of non-small cell lung cancer (NSCLC). Methods A total of 57 patients with newly diagnosed NSCLC who underwent radical resection of lung cancer in the Affiliated Hospital of Medical College of Jiaying University were selected as the NSCLC group between January 2019 and July 2020. Meanwhile, 52 patients with benign lung diseases (benign group) and 58 healthy people (healthy group) were selected as the control group. Seven tumor-related autoantibodies, including, tumor suppressor gene p53 (p53), protein gene product 9.5 (PGP9.5), sex determining region Y-box2 (SOX2), G antigen 7(GAGE7), tumor antigen (GBU4-5), cancer associated gene (GAGE) and melanoma antigen 1 (MAGE A1) were detected by ELISA. The receiver operating characteristic (ROC) curve was used to analyze the value of above seven tumor-related autoantibodies in the diagnosis of NSCLC. Results The levels of p53, PGP9.5, SOX2, GAGE7, GBU4-5, GAGE and MAGE A1 in the NSCLC group were higher than those in the benign group and the healthy group, and the differences were statistically significant (P<0.05). The area under curve values of p53, PGP9.5, SOX2, GAGE7, GBU4-5, GAGE,and MAGE A1 alone for diagnosing NSCLC were all larger than 0.6 (P<0.05), indicating certain diagnostic value. According to the largest Youden index, the cut-off values determined were 1.57 U/ml, 12.92 U/ml, 12.67 U/ml, 14.64 U/ml,8.45 U/ml, 10.65 U/ml, and 7.68 U/ml, respectively. For single diagnosis, the sensitivity of p53 was the highest(91.20%), followed by GAGE (68.40%), and GP 9.5 and GAGE7 (both 59.60%). Conclusion All of the 7 tumor-associated autoantibodies have certain value in the diagnosis of NSCLC.
陈美任. 多种肿瘤相关自身抗体在非小细胞肺癌中的诊断效果分析[J]. 中国当代医药, 2021, 28(28): 54-56-60.
CHEN Mei-ren. Value of multiple tumor-associated autoantibodies in the diagnosis of nonsmall cell lung cancer. 中国当代医药, 2021, 28(28): 54-56-60.
Goldstraw P,Chansky K,Crowley J,et al.The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth)Edition of the TNM Classification for Lung Cancer[J].J Thorac Oncol,2016,11(1):39-51.